Literature DB >> 12507204

Rectal cancer: the sphincter-sparing approach.

David M Ota1, Lisa Jacobs, Boris Kuvshinoff.   

Abstract

There is considerable skepticism regarding sphincter-preserving surgery for rectal cancer, and 40% to 60% APR rates are reported in many prospective studies. Despite radical surgery, 20% positive margin rates are frequently reported. Rectal carcinoma responds to preoperative chemoradiation therapy with a 10% to 15% pathologic complete response rate. Preoperative therapy offers an opportunity to reduce the positive margin rate and to reduce the APR rate. Because there is significant tumor regression with preoperative therapy, distal margins of less 1 cm are acceptable and do not result in suture line recurrence. APR rate of less than 10% is feasible and better chemotherapy with radiation therapy will reduce the APR to less than 5%.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12507204     DOI: 10.1016/s0039-6109(02)00048-8

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  4 in total

1.  Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.

Authors:  Y Nancy You; Nancy N Baxter; Andrew Stewart; Heidi Nelson
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

2.  Defining the distal margin of rectal cancer for surgical planning.

Authors:  Sumito Sato; Takashi Kato; Jun-Ichi Tanaka
Journal:  J Gastrointest Oncol       Date:  2017-02

3.  Outcomes of resection for rectal cancer in India: the impact of the double stapling technique.

Authors:  Shailesh V Shrikhande; Rajesh R Saoji; Savio G Barreto; Anagha C Kakade; Stephen D Waterford; Sanjay B Ahire; Fahim M Goliwale; Parul J Shukla
Journal:  World J Surg Oncol       Date:  2007-03-21       Impact factor: 2.754

4.  Combination of three-gene immunohistochemical panel and magnetic resonance imaging-detected extramural vascular invasion to assess prognosis in non-advanced rectal cancer patients.

Authors:  Xiao-Fu Li; Zheng Jiang; Ying Gao; Chun-Xiang Li; Bao-Zhong Shen
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.